New hope for transplant patients with rare kidney disease
NCT ID NCT04572854
First seen May 01, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This study tested a drug called pegcetacoplan in 13 adults whose rare kidney disease (C3G or IC-MPGN) came back after a kidney transplant. The goal was to see if the drug could safely reduce signs of disease in kidney tissue. Participants received the drug or standard care, and researchers checked kidney biopsies for improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUV
Lausanne, 1005, Switzerland
-
CUIMC
New York, New York, 10032, United States
-
Center Hospitalier Universitaire de Montpellier
Montpellier, 34295 CEDEX 5, France
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Clinical Research Center, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, 05403-000, Brazil
-
Freeman Hospital
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Hopital Edouard Herriot, Hospices Civils de Lyon
Lyon, 69437, France
-
Hospital Universitario 12 de Octubre, Nephrology Department
Madrid, 28041, Spain
-
Hospital Universitario Fundacion Favaloro
Buenos Aires, C1093AAS, Argentina
-
Hospital de Alta Complejidad en Red El Cruce Dr. Nestor Carlos Kirchner
San Juan Bautista, Buenos Aires, B1888AAE, Argentina
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
-
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90020-090, Brazil
-
Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Ranica, 24020, Italy
-
Keck School of Medicine, University of Southern California
Los Angeles, California, 900033, United States
-
Lille Regional University Hospital Center, Claude Huriez Hospital, Department of Nephrology
Lille, 59000, France
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Medical University of Vienna
Vienna, 1090, Austria
-
Monash Medical Centre
Clayton, 3168, Australia
-
NYU Langone Health Transplant Insitute
New York, New York, 10016, United States
-
Radbound University Medical Center
Nijmegen, 6500 HB, Netherlands
-
Santa Casa de Misericordia de Belo Horizonte
Belo Horizonte, CEP 30150-221, Brazil
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - FMB/UNESP
Botucatu, São Paulo, 18618-686, Brazil
-
Washington University, St.Louis
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.